Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

• Status: Terminated
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to test a clinical benefit of the addition of CP 751,871 to erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The primary endpoint is Overall Survival (OS).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Antibodies, Monoclonal; Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Non small cell lung cancer with a primary histology of squamous cell, large cell or adenosquamous carcinoma. At least 1 measurable lesion, as defined by RECIST.

Exclusion Criteria:

• Primary NSCLC adenocarcinoma and its subtypes or unknown/unspecified histology.

• Prior Erlotinib therapy.

• Prior anti IGF IR based investigational therapy.